目的 分析2017年1月—2019年12月天津市肿瘤医院（天津医科大学肿瘤医院）抗肿瘤分子靶向药使用情况，为临床合理用药及抗肿瘤新药研发提供参考。方法 收集天津市肿瘤医院2017年1月—2019年12月期间抗肿瘤分子靶向药品种/品规数、使用金额、在抗肿瘤药使用金额中的构成比，并对用药频度（DDDs）、限定日费用（DDC）及排序比（B/A）进行回顾性分析。结果 2017—2019年，本院抗肿瘤分子靶向药品由11种增至30余种；使用金额及在抗肿瘤药使用金额中的构成比呈逐年快速增长趋势，3年来使用金额由0.28亿元增长至3.65亿元，增加了12倍多，构成比从9.31%增至41.57%；各抗肿瘤分子靶向药DDDs也大幅增加，其中以贝伐珠单抗、曲妥珠单抗增幅居前列；而DDC逐年下降，降幅大于25%，随之，多数药物B/A值逐渐接近或大于1，使用金额与DDDs趋于一致。结论 本院抗肿瘤分子靶向药物使用与本院收治患者人群特征和指南治疗方案基本一致，使用基本合理；医改新政策出台，分子靶向药纳入医保，药品价格大幅下降，患者治疗费用降低，使得更多患者的治疗与国际接轨，提高了治疗的有效率，成为新医改政策的直接受益者。

Objective To investigate the utilization of molecular targeted antineoplastic drugs in Tianjin Cancer Hospital from 2017 to 2019, and provide reference for rational clinical uses and antitumor drugs research and development. Methods By retrospective survey, the utilization of molecular targeted antineoplastic drugs in Tianjin Cancer Hospital during 2017—2019 was analyzed in terms of consuption sum, DDDs, DDC and sorting ratio (B/A). Results The categories of molecular targeted antineoplastic drugs increased significantly year by year, the categories increased from 11 varieties in 2017 to 30 varieties in 2019; and quantities increased from 0.28 billion in 2017 to 3.65 billion in 2019, rising nearly 12-fold from 2017 to 2019; as well as the proportions of that to antineoplastic drugs, it increased from 9.31% to 41.57%, The DDDs of molecular targeted antineoplastic drugs increased significantly, Bevacizumab, Sorafenib and Trastuzumab took up the top growth list; the B/A values of most drugs were well synchronized. And the DDC values of molecular targeted antineoplastic drugs were reduced after due to the health insurance, Imatinib, Cetuximab, Gefitinib etc. 9 categories reduced by more than 50%. Conclusion The applications of molecular targeted antineoplastic drugs are well synchronize with the characteristics of patients and guideline in Tianjin Cancer Hospital, the applications are basically rational; the prices of molecular targeted antineoplastic drugs are reduced due to the health insurance, molecular targeted antineoplastic drugs incorporated into Medical Insurance Policy, which is helpful to reduce the health care burdens of residents. The patients can follow the international first-line treatment, and become the direct beneficiary of health reform.

R979.1